`
`U.S. Patent No. 9,220,631
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`Regeneron Pharmaceuticals, Inc.,
`
`Petitioner
`
`v.
`
`Novartis Pharma AG, Novartis Technology LLC, and Novartis
`Pharmaceuticals Corporation,
`
`Patent Owners.
`
`
`
`U.S. Patent No. 9,220,631 to Sigg et al.
`
`IPR2020-01317
`
`
`
`
`
`
`
`
`
`
`
`
`PATENT OWNERS’ SUBMISSION OF MANDATORY NOTICE
`INFORMATION UNDER 37 C.F.R. § 42.8(a)(2)
`
`
`
`
`
`
`
`
`
`
`
`
`U.S. Patent No. 9,220,631
`
`
`
`Pursuant to 37 C.F.R. § 42.8(a)(2), Patent Owners Novartis Pharma AG,
`
`Novartis Technology LLC, and Novartis Pharmaceuticals Corporation
`
`(collectively, “Patent Owners”) file their Mandatory Notices. This notice is timely
`
`filed within 21 days of the purported date of service of the petition on July 16,
`
`2020.
`
`I.
`
`
`
`37 C.F.R. § 42.8(b)(1) – REAL PARTY-IN-INTEREST
`
`The patent owners and real parties-in-interest are Novartis Pharma AG,
`
`Novartis Technology LLC, and Novartis Pharmaceuticals Corporation.
`
`II.
`
`37 C.F.R. § 42.8(b)(2) – RELATED MATTERS
`
`
`
`Pursuant to 37 C.F.R. § 42.8(b)(2), Patent Owners identify the following
`
`district court and administrative proceedings that would affect, or may be affected
`
`by, a decision in this proceeding:
`
` Novartis Pharma AG et al v. Regeneron Pharmaceuticals, Inc., No. 1:20-cv-
`
`00690-TJM-CFH (NDNY)
`
` Regeneron Pharmaceuticals Inc. v. Novartis Pharma AG et al, 1:20-cv-
`
`05502-AJN (SDNY)
`
` International Trade Commission Inv. No. 337-1207, Certain Pre-Filled
`
`Syringes for Intravitreal Injection and Components Thereof
`
` IPR2020-01318 (Patent No. 9,220,631), Regeneron Pharmaceuticals, Inc. v.
`
`Novartis Pharma AG, et al.
`
`2
`
`
`
`U.S. Patent No. 9,220,631
`
`III.
`
`37 C.F.R. § 42.8(b)(3) – DISCLOSURE OF COUNSEL
`
`
`
`Pursuant to 37 C.F.R. § 42.8(b)(3), Patent Owner identifies lead and back-up
`
`counsel as follows:
`
`Lead Counsel:
`
`Backup Counsel:
`
`Elizabeth J. Holland (Reg. No. 47,657)
`Goodwin Procter LLP
`620 Eighth Avenue
`New York, NY 10018
`Phone: (212) 813-8800
`Fax: (212) 355-3333
`EHolland@goodwinlaw.com
`
`
`Backup Counsel:
`
`Linnea Cipriano (Reg. No. 67,729)
`Goodwin Procter LLP
`620 Eighth Avenue
`New York, NY 10018
`Phone: (212) 813-8800
`Fax: (212) 355-3333
`LCipriano@goodwinlaw.com
`
`
`
`
`William G. James (Reg. No. 55,931)
`Goodwin Procter LLP
`1900 N Street, N.W.
`Washington, D.C. 20036
`Phone: (202) 346-4000
`Fax: (202) 346-4444
`WJames@goodwinlaw.com
`
`
`Backup Counsel:
`
`Joshua Weinger (Reg. No. 73,198)
`Goodwin Procter LLP
`100 Northern Avenue
`Boston, MA 02210
`Phone: (617) 570-1000
`Fax: (617) 523-1231
`JWeinger@goodwinlaw.com
`
`IV. 37 C.F.R. § 42.8(b)(4) – CORRESPONDENCE
`
`
`
`Pursuant to 37 C.F.R. § 42.8(b)(4), Patent Owners request that all electronic
`
`correspondence be directed to lead counsel and back-up counsel identified in
`
`Section III above. Patent Owner consents to electronic service at the following e-
`
`mail address: DG-NovartisPFS@goodwinlaw.com.
`
`3
`
`
`
`Dated: August 6, 2020
`
`
`
`By:
`
`
`
`
`
`U.S. Patent No. 9,220,631
`
`
`
`
`/Elizabeth J. Holland/
`Elizabeth J. Holland (Reg. No. 47,657)
`Lead Counsel for Patent Owners
`Goodwin Procter LLP
`620 Eighth Avenue
`New York, NY 10018
`Phone: (212) 813-8800
`Fax: (212) 355-3333
`EHolland@goodwinlaw.com
`
`4
`
`
`
`
`
`
`
`
`
`U.S. Patent No. 9,220,631
`
`CERTIFICATE OF SERVICE
`A copy of this Patent Owners’ Mandatory Notices has been served on
`
`Petitioner’s attorneys of record as follows via electronic mail:
`
`Elizabeth Stotland Weiswasser
`Weil, Gotshal & Manges LLP
`767 Fifth Avenue
`New York, NY 10153
`T: 212-310-8022
`F: 212-310-8007
`elizabeth.weiswasser@weil.com
`USPTO Reg. No. 55,721
`Anish R. Desai
`Weil, Gotshal & Manges LLP
`767 Fifth Avenue
`New York, NY 10153
`T: 212-310-8730
`F: 212-310-8007
`anish.desai@weil.com
`USPTO Reg. No. 73,760
`
`Natalie Kennedy
`Weil, Gotshal & Manges LLP
`767 Fifth Avenue
`New York, NY 10153
`T: 212-310-8730
`F: 212-310-8007
`natalie.kennedy@weil.com
`USPTO Reg. No. 68,511
`Andrew Gesior
`Weil, Gotshal & Manges LLP
`767 Fifth Avenue
`New York, NY 10153
`T: 212-310-8730
`F: 212-310-8007
`andrew.gesior@weil.com
`
`
`
`U.S. Patent No. 9,220,631
`
`USPTO Reg. No. 76,588
`
`Brian E. Ferguson
`Weil, Gotshal & Manges LLP
`2001 M Street, N.W., Suite 600
`Washington, D.C. 20036
`T: 202-682-7000
`F: 202-857-0940
`brian.ferguson@weil.com
`USPTO Reg. No. 36,801
`
`Christopher M. Pepe
`Weil, Gotshal & Manges LLP
`2001 M Street, N.W., Suite 600
`Washington, D.C. 20036
`T: 202-682-7000
`F: 202-857-0940
`christopher.pepe@weil.com
`USPTO Reg. No. 73,851
`
`Regeneron.IPR.Service@weil.com
`
`Attorneys for Regeneron Pharmaceuticals, Inc.
`
`
`
`Dated: August 6, 2020
`
`By:
`/Elizabeth J. Holland/
`Elizabeth J. Holland (Reg. No. 47,657)
`Lead Counsel for Patent Owners
`Goodwin Procter LLP
`620 Eighth Avenue
`New York, NY 10018
`Phone: (212) 813-8800
`Fax: (212) 355-3333
`EHolland@goodwinlaw.com
`
`
`
`2
`
`